LILRA4 Antibody

Basic Research Questions

• What is LILRA4 and how should researchers approach antibody selection for its detection?

LILRA4, also known as ILT7 and CD85g, is a 499 amino acid type I transmembrane glycoprotein containing four Ig-like domains in its extracellular region. It is selectively expressed on plasmacytoid dendritic cells (pDCs) and plays a critical role in regulating immune responses .

When selecting antibodies for LILRA4 detection, researchers should consider:

• Epitope recognition: Antibodies targeting different domains (D1-D4) may provide distinct sensitivity and specificity profiles. For example, antibodies targeting the Glu24-Asn446 region (the extracellular domain) are commonly used for flow cytometry applications .

• Clone validation: Validated clones such as 656688 and 656656 have demonstrated specificity in multiple applications .

• Application compatibility: Some antibodies work better for particular applications. For instance, clone 4B3E4 is recommended for ELISA, flow cytometry, and IHC, while polyclonal antibodies like A09611 may be preferred for Western blot applications .

To ensure optimal results, researchers should validate antibodies using both positive controls (plasmacytoid dendritic cells) and negative controls (cell types that do not express LILRA4).

• What methodological approaches are recommended for detecting LILRA4 expression using flow cytometry?

Flow cytometry is a primary method for detecting LILRA4 expression on pDCs. Based on established protocols, researchers should follow these methodological steps:

• Cell preparation: Isolate peripheral blood mononuclear cells (PBMCs) using density gradient centrifugation.

• Surface staining: Label cells with anti-LILRA4 antibody (recommended dilution 1:50-1:200, optimize for specific antibody) .

• Secondary detection: Use appropriate fluorochrome-conjugated secondary antibodies if using unconjugated primary antibodies.

• Co-staining strategy: Include markers for pDC identification such as BDCA-2/CLEC4C (as demonstrated in the validation data for MAB6287) .

• Gating strategy:

  • First gate on viable cells (using viability dye)

  • Gate on singlets

  • Gate on lineage-negative cells (CD3-, CD14-, CD19-, CD56-)

  • Identify pDCs as BDCA-2+ cells

  • Assess LILRA4 expression on this population

Control settings should be established using appropriate isotype controls (e.g., MAB003) . For optimal detection, consider using directly conjugated antibodies (such as Alexa Fluor 647-conjugated antibodies) to minimize background and increase signal-to-noise ratio .

• What experimental conditions affect LILRA4 antibody binding and how can researchers optimize detection sensitivity?

Several experimental conditions significantly impact LILRA4 antibody binding efficacy:

For optimizing detection sensitivity:

• Titrate antibody concentrations to determine optimal signal-to-noise ratio

• Consider signal amplification systems for low expression levels

• Use APC or PE conjugates for detecting low abundance targets

• For pDCs specifically, be aware that TLR9 signaling can down-regulate LILRA4 expression, potentially affecting detection

• What are the recommended storage and handling protocols for maintaining LILRA4 antibody functionality?

Proper storage and handling are critical for maintaining antibody functionality. Based on manufacturer recommendations:

Long-term storage:

• Store at -20°C to -70°C for up to 12 months from receipt date

• Use manual defrost freezers to avoid temperature fluctuations

• Avoid repeated freeze-thaw cycles

Short-term storage:

• For frequent use within one month, store at 2-8°C under sterile conditions after reconstitution

• For mid-term storage (up to 6 months), store at -20°C to -70°C under sterile conditions after reconstitution

Handling considerations:

• Reconstitute lyophilized antibodies carefully according to manufacturer specifications

• Centrifuge vials briefly before opening to collect all material

• Consider aliquoting reconstituted antibodies to minimize freeze-thaw cycles

• For optimal stability, some LILRA4 antibodies are provided in buffers containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide

Following these protocols ensures maximum retention of binding capacity and specificity for experimental applications.

• How should researchers validate LILRA4 antibody specificity and what controls are essential?

Thorough validation of LILRA4 antibody specificity requires multiple approaches:

Essential validation strategies:

• Cell type specificity: Test antibody on pDCs (positive control) versus other cell types (negative controls)

• Knock-down/knockout validation: Use siRNA or CRISPR-Cas9 to reduce/eliminate LILRA4 expression and confirm loss of signal

• Peptide blocking: Pre-incubate antibody with immunizing peptide to demonstrate specific epitope recognition

• Cross-reactivity assessment: Test against other LILR family members, particularly those with high sequence homology

Required controls:

• Isotype controls: Match the isotype of the primary antibody (e.g., IgG1 for many LILRA4 mAbs)

• Secondary-only controls: To assess background from secondary detection reagents

• FMO (Fluorescence Minus One): For multicolor flow cytometry to set proper gating boundaries

• Blocking controls: Pre-incubate cells with unlabeled antibody before adding labeled antibody to confirm specific binding

Researchers should be particularly vigilant about cross-reactivity with other LILR family members, as demonstrated in antibody development campaigns where cross-reactivity testing with LILRB1-5 and LILRA1-6 was necessary to ensure specificity .

Advanced Research Questions

• What methodologies are most effective for studying LILRA4-BST2 interactions and their impact on plasmacytoid dendritic cell function?

Studying LILRA4-BST2 interactions requires sophisticated methodological approaches:

Protein-protein interaction assays:

• BioLayer Interferometry (BLI): This technique measures binding affinities between recombinant LILRA4 and BST2. The protocol includes loading antibody (30 μg/mL) onto protein G biosensors, followed by exposure to varying concentrations of recombinant LILRA4 (0.1-200 nM). Data analysis using 1:1 binding models can extract association and dissociation rates, with Kd calculated as koff/kon .

• Functional LILRA4-BST2 blocking assays: Design competitive assays where plates are pre-coated with recombinant ligand (10 μg/ml) before adding cells expressing LILRA4 and measuring signaling outcomes .

Signaling pathway analysis:

• Chimeric receptor reporter systems: Construct chimeric receptors where the extracellular domain of LILRA4 is fused to the intracellular domain of signaling receptors like PILR-β. When an agonist antibody binds and activates the chimeric receptor, GFP expression increases, while antagonist antibodies decrease expression .

• Type I IFN production assay: Stimulate pDCs with TLR7/9 agonists in the presence/absence of LILRA4-targeting antibodies, then measure IFN-α/β production by ELISA or bioassay. This approach directly assesses the functional consequence of LILRA4 engagement .

• Calcium mobilization assays: Since LILRA4 engagement affects calcium signaling, use calcium-sensitive dyes to monitor real-time changes in intracellular calcium following antibody treatment of pDCs .

These methods provide complementary insights into both the physical interactions between LILRA4 and its ligands and the functional consequences of these interactions on pDC biology.

• How can researchers develop and characterize LILRA4-targeting antibody-drug conjugates (ADCs) for therapeutic applications?

Developing effective LILRA4-targeting ADCs requires methodical characterization of several critical parameters:

Antibody selection and engineering:

• First, select antibodies with optimal properties:

  • High affinity (single-digit nM range)

  • Specific binding to LILRA4 without cross-reactivity to other LILR family members

  • Capacity to induce receptor internalization

• Generate Fc-engineered variants to reduce effector functions:

  • N297A or N297Q mutations to eliminate Fc gamma receptor binding

  • These modifications improve the pharmacokinetic profile and reduce off-target effects

ADC assembly and characterization:

• Introduce linker attachment sites:

  • Site-specific conjugation using enzymatic approaches (e.g., microbial transglutaminase targeting Q295/Q297)

  • This generates homogeneous ADCs with defined drug-to-antibody ratios (DAR)

• Install cytotoxic payloads:

  • Connect antimitotic agents such as monomethyl auristatin F (MMAF) using strategies like strain-promoted azide-alkyne click chemistry

Functional validation methods:

• Internalization assays: Measure LILRA4 downregulation on target cells (e.g., THP-1) after antibody incubation at 37°C for 24h, comparing surface LILRA4 levels to untreated controls using flow cytometry

• Binding preservation: Confirm that conjugation hasn't compromised target binding using ELISA assays with plates coated with recombinant LILRA4 protein (1 μg/mL)

• In vitro cytotoxicity: Test ADC potency against LILRA4-positive cell lines and patient-derived samples, including appropriate negative controls

• Pharmacokinetic analysis: Measure plasma concentrations following IV administration (3 mg/kg) with sampling at multiple timepoints (15 min to 336h) using ELISA detection methods that distinguish between total antibody and intact ADC

This methodical approach ensures development of optimal LILRA4-targeting ADCs with appropriate specificity, potency, and pharmacokinetic properties.

• What techniques are most effective for investigating LILRA4's role in immunosuppression within tumor microenvironments?

Investigating LILRA4's immunosuppressive functions requires integrated approaches:

Ex vivo tumor microenvironment analysis:

• Multi-parameter flow cytometry: Analyze LILRA4 expression on pDCs infiltrating tumor samples, correlating with exhaustion markers and functional states. Include markers for:

  • pDC identification (BDCA-2)

  • Activation status (CD80, CD86)

  • Exhaustion markers (PD-1, TIM-3)

  • Cytokine production capacity (intracellular IFN-α)

• Spatial profiling: Apply multiplexed immunofluorescence or imaging mass cytometry to map LILRA4+ cells relative to tumor cells and T cells within tissue architecture.

Functional immunosuppression assays:

• Mixed lymphocyte reaction (MLR): This assay evaluates how LILRA4 engagement affects pDC-mediated T cell activation:

  • Isolate pDCs from patient samples or healthy donors

  • Treat with LILRA4-targeting antibodies (agonists or antagonists)

  • Co-culture with allogeneic T cells

  • Measure T cell proliferation (CFSE dilution) and activation marker upregulation (CD25, CD69)

  • Assess cytokine production (IL-2, IFN-γ)

• Reprogramming assessment: Evaluate how LILRA4 targeting affects pDC phenotype conversion:

  • Measure changes in surface expression of HLA-DR, HLA-ABC, CD86 (upregulated with successful reprogramming) and CD206 (downregulated)

  • Analyze transcriptional changes using RNA-seq or targeted gene expression panels

• Reverse T cell suppression assays: In tumors like AML, blocking LILRA4 can reverse T cell suppression, which can be measured through:

  • T cell functional recovery (cytokine production, proliferation)

  • Cytotoxicity against tumor targets

  • Upregulation of activation markers

These methodologies provide comprehensive insights into how LILRA4 contributes to immunosuppression and how therapeutic targeting might restore anti-tumor immunity.

• How should researchers design experiments to investigate differential expression and regulation of LILRA4 in disease states?

Investigating LILRA4 expression and regulation in disease contexts requires systematic experimental design:

Clinical sample analysis workflow:

• Single-cell transcriptomics: Apply scRNA-seq to dissect heterogeneity in LILRA4 expression:

  • Isolate cells from disease and control samples

  • Perform quality control filtering and normalization

  • Identify cell clusters expressing LILRA4

  • Compare expression patterns across disease states

  • This approach successfully identified LILRA4high pre-mature plasma cell clusters in multiple myeloma patients with poor survival (less than 24 months)

• Multi-omics integration:

  • Combine ATAC-seq with transcriptomics to identify regulatory mechanisms

  • ATAC-seq can reveal pronounced chromosomal accessibility changes that drive LILRA4 upregulation, as demonstrated in MM studies

  • Correlate epigenetic modifications with LILRA4 expression levels

• Prognostic correlation:

  • Stratify patients based on LILRA4 expression levels

  • Perform survival analysis using appropriate statistical methods

  • Evaluate correlation with established disease markers

  • This approach has revealed that high LILRA4 expression correlates with poor prognosis in newly diagnosed and relapsed/refractory MM patients

Mechanistic investigation methods:

• Genetic manipulation:

  • Apply CRISPR-Cas9 deletion of LILRA4 to study functional consequences

  • Construct inducible expression systems to study dose-dependent effects

  • These approaches have demonstrated that LILRA4 deletion alleviates MM cell growth

• Activation/regulation studies:

  • Test how TLR7/9 agonists regulate LILRA4 expression

  • Examine how inflammatory cytokines modulate receptor levels

  • Investigate ligand-induced receptor internalization and recycling

These systematic approaches provide both correlative clinical insights and mechanistic understanding of LILRA4's role in disease pathogenesis.

• What are the methodological considerations for developing LILRA4 antibodies as immunotherapeutic agents in cancer and neurodegenerative diseases?

Developing LILRA4 antibodies as therapeutics requires careful consideration of multiple factors:

Target engagement optimization:

• Epitope selection:

  • For blocking antibodies, target the loop between D1-D2 domains which mediates interactions with ligands like ApoE

  • For depleting antibodies, target epitopes with minimal internalization

  • Crystallography and mutagenesis studies have identified critical binding regions

• Antibody format engineering:

  • Consider humanization strategies to reduce immunogenicity

  • Select optimal isotypes based on mechanism of action (IgG1 for ADCC/ADCP, IgG4 for blocking without effector functions)

  • The humanized mAb h128-3 demonstrated efficacy in AML models through multiple mechanisms

Mechanism of action validation:
For cancer applications (e.g., AML, MM), evaluate:

• T cell suppression reversal: Measure restoration of T cell function after LILRA4 blockade

• Inhibition of tissue infiltration: Assess reduction in tumor cell invasiveness

• Effector functions: Quantify antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP)

• Synergy with standard therapies: Evaluate combination with chemotherapy to enhance mobilization of leukemia cells

For neurodegenerative applications (e.g., Alzheimer's):

• Microglial activation: Measure enhanced microglial phagocytosis of amyloid plaques

• Amyloid clearance: Quantify reduction in amyloid load in animal models

• Behavioral assessment: Evaluate improvement in cognitive function in disease models

• ApoE interaction blockade: Verify that antibodies block LILRA4-ApoE interactions which are implicated in microglial dysfunction

Translational model considerations:

• Appropriate disease models:

  • Patient-derived xenograft (PDX) models

  • Syngeneic immunocompetent models

  • Transgenic models expressing human LILRA4

• Clinical parameter improvement:

  • For AML: Reduction in blast counts, improved survival

  • For MM: Reduced tumor burden, inhibition of MDSC function

  • For Alzheimer's: Reduced amyloid load, improved cognitive function

These methodological considerations provide a framework for developing LILRA4-targeting antibodies with optimal therapeutic potential across different disease contexts.